You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动|康哲药业(00867.HK)续升5%中期净利增长22.2%
格隆汇 08-20 09:52
格隆汇8月20日丨康哲药业(00867.HK)今日股价续涨5.19%,报8.11港元,暂成交2573万港元,最新总市值200.169亿港元。

康哲药业日前发布2019年中期业绩,中期股东应占溢利增22.2%至11.7亿元,每股派0.19元。公告显示,若将“两票制”收入还原则营业额增长14.4%至34.02亿元。收入增长主要因为产品销售数量的增加。
中金公司昨日报告称,减税带来公司盈利能力提升,期待更多催化剂,维持跑赢行业评级。
值得一提的是,从2010年开始,康哲就陆续通过买断产品权利、独家代理两种方式引进跨国药企独家、原研产品,创造了独特的“康哲模式”。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account